Date: 2015-01-12
Type of information: Financing round
Company: UroSens (UK)
Investors: Longwall Venture Partners (UK) Northstar Ventures (UK) Esperante BV (The Netherlands) Cambridge Capital Group (UK) and other existing shareholders.
Amount: £2 million
Funding type: financing round
Planned used: The new funding will enable UroSens to expand its commercial and technical teams, finalise product development and begin to commercialise its diagnostic test, the UroSens Mcm5-ELISA, for prostate and bladder cancer. Mcm5 (minichromosome maintenance complex component 5) is a protein which only appears when cells divide, and is an excellent marker for the presence of dividing cancer cells. The Company is also seeking to undertake further clinical trials in Europe and the United States to expand the applications of the Mcm5 test. In addition, UroSens will continue the development of a Point-of-Care version of the Mcm5 test.
Others: * On January 12, 2015, UroSens Ltd, a diagnostic company developing novel, non-invasive urine tests for the detection of prostate and bladder cancer, has announced it has received £2 million ($3.02 million) investment. The funding round was led by Longwall Venture Partners, with participation from shareholders including Northstar Ventures, Esperante BV, Cambridge Capital Group and other existing shareholders.
Therapeutic area: Cancer - Oncology - Diagnostic
